Abstract library

894 results for "radionuclide therapy".
#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm
Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Medical Student Michala Danielle Zacho
#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Olfat Kamel Hasan
#2847 Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Noémie S Minczeles
#2734 Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review
Introduction: Therapy-related myeloid neoplasm (t-MN) has been reported as a potential long-term and frequently lethal adverse event after PRRT in NET. However, the incidence, time of diagnosis, and nature of t-MN is unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: DR Mohamad Sonbol
Authors: Sonbol M, Hilal T, Halfdanarson T, ...
#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review
Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christopher Wee
Authors: Wee C, Dundar A, Packard A, Kendi A T, ...
#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christine Merkel
#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study
Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Mercedes Mitjavila Casanovas
#2919 Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs
Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: A/Prof Nick Pavlakis
#2756 Theranostic Implication of Molecular Imaging Phenotype of Well-Differentiated Lung Carcinoid by 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT
Introduction: Well-differentiated pulmonary neuroendocrine tumour, classified as typical carcinoid (TC) and atypical carcinoid (AC), is a heterogenous disease with variable clinical behaviour.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Lamiaa Zidan
Authors: Zidan L, Iravani A, Kong G, Akhurst T, ...
#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing
Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia